1. MAPK/ERK Pathway
  2. p38 MAPK

p38 MAPK

The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.

The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.

p38 MAPK Related Products (37):

Cat. No. Product Name Effect Purity
  • HY-10256
    SB 203580 Inhibitor 99.54%
    SB 203580 is a widely used p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM. It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.
  • HY-10295
    SB 202190 Inhibitor 99.12%
    SB 202190 is a cell-permeable p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38 and p38β2, respectively.
  • HY-10320
    Doramapimod Inhibitor 99.72%
    Doramapimod (BIRB 796) is a highly potent p38 MAPK inhibitor with an IC50 of 4 nM. It also inhibits B-Raf with an IC50 of 83 nM.
  • HY-13241
    LY2228820 Inhibitor 99.98%
    LY2228820 is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively.
  • HY-10256A
    SB 203580 hydrochloride Inhibitor 99.71%
    SB 203580 hydrochloride is a widely used p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM. It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.
  • HY-16782
    Pexmetinib Inhibitor 98.30%
    Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.
  • HY-112182
    UM-164 Inhibitor 99.08%
    UM-164 is a highly potent inhibitor of c-Src with a Kd of 2.7 nM. UM-164 also potently inhibits p38α and p38β.
  • HY-103672
    AZD7624 Inhibitor
    AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity.
  • HY-11068
    SB 239063 Inhibitor 99.53%
    SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α).
  • HY-10402
    Losmapimod Inhibitor
    Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.
  • HY-10578
    PD 169316 Inhibitor 98.33%
    PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM.
  • HY-P0117
    Tat-NR2B9c Inhibitor 98.22%
    Tat-NR2B9c is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1; Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy. Sequence: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val.
  • HY-10406
    Talmapimod Inhibitor 98.07%
    SCIO-469 is a selective ATP-competitive p38 inhibitor with IC50 of 9 nM for p38αin vitro, about 10-fold selectivity for p38α over p38β, and at least 2000-fold selectivity for p38α over an in vitro panel of 20 other kinases, including other MAK kinases.
  • HY-10456
    TAK-715 Inhibitor 99.93%
    TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1.
  • HY-N0674A
    Dehydrocorydaline chloride Activator 99.95%
    Dehydrocorydaline chloride is an alkaloidal that has anti-inflammatory and anti-cancer activities. Dehydrocorydaline chloride can elevate p38 MAPK activation.
  • HY-10328
    Neflamapimod Inhibitor 98.74%
    VX-745 is a potent and selective inhibitor of p38α, and possesses anti-inflammatory activity.
  • HY-10401
    VX-702 Inhibitor 99.54%
    VX-702 is a highly selective inhibitor of p38α MAPK(IC50=4 -20 nM), 14-fold higher potency against the p38α versus p38β.
  • HY-14975
    R1487 Hydrochloride Inhibitor 98.68%
    R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38α.
  • HY-10403
    PH-797804 Inhibitor 98.59%
    PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM; 4-fold more selective versus p38β and does not inhibit JNK2.
  • HY-12511
    SKF-86002 Inhibitor 99.51%
    SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 μM).
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.